文献速递血管炎

鼻部金黄色葡萄球菌定植与复方磺胺甲噁唑使用或ANCA相关性血管炎复发无明确关联

No evident association of nasal carriage of Staphylococcus aureus or its small-colony variants with cotrimoxazole use or ANCA-associated vasculitis relapses.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该研究纳入法国国家血管炎转诊中心的ANCA相关性血管炎(AAV)患者及非AAV对照,通过双侧前鼻拭子培养检测金黄色葡萄球菌(SA)及其小菌落变异型(SCV)定植,分析其与复方磺胺甲噁唑(CTX)使用及AAV复发的关系。结果显示AAV各亚型间鼻SA定植率无差异,CTX预防者鼻SA定植较少,但鼻SA或SCV定植及CTX使用均未改变复发率、BVAS或ANCA阳性状态。

要点

  • AAV各亚型间鼻SA定植率无显著差异(P=0.53)。
  • 服用CTX预防的AAV患者鼻SA定植率低于未服用者(8.7% vs 36.2%,P=0.02)。
  • 鼻SA或SCV定植及CTX使用均未改变AAV复发率、BVAS或ANCA阳性状态。

核心结论

  • 鼻SA或SCV定植在AAV各亚型间相当,但高于对照。
  • 鼻SA或SCV定植及CTX使用未改变AAV复发率。

研究设计与样本

  • 纳入法国国家血管炎转诊中心2012年9月至2013年5月连续AAV患者(GPA、EGPA、MPA)及因SA/SCV定植比较而住院的非AAV对照。
  • 所有受试者行双侧前鼻拭子培养,定植状态与复发、BVAS、ANCA阳性、抗葡萄球菌及免疫抑制剂使用在入组后至少4年进行分析。

主要发现

  • 鼻SA定植率在GPA为30%(24/80)、EGPA为25%(7/28)、MPA为27.3%(3/11),组间P=0.53。
  • 对照鼻SA定植率低于未服用CTX的GPA患者(P=0.04)。
  • 服用CTX预防的AAV患者鼻SA定植率为8.7%,未服用者为36.2%(P=0.02)。
  • 鼻SCV定植见于15/207(7.2%)患者,GPA为41.7%(10/24)、MPA为28.6%(2/7)、EGPA为66.7%(2/3),高于对照的7.1%(1/14)(P=0.02)。
  • 仅抗PR3 ANCA患者中观察到SCV定植者BVAS有升高趋势。

临床怎么用

  • CTX预防与较低的鼻SA定植率相关,但未观察到对AAV复发率的影响。
  • 鼻SA或SCV定植状态不宜单独用于预测AAV复发。

局限性

  • 对照仅用于SA/SCV定植比较,非AAV对照样本量较小。
  • SCV定植组样本量有限,尤其EGPA和MPA亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify the role of Staphylococcus aureus (SA) or its intracellular small-colony variant phenotype (SCV) with co-trimoxazole (CTX) or ANCA-associated vasculitis (AAV) activity. METHODS: All consecutive AAV patients with granulomatosis with polyangiitis (GPA), eosinophilic GPA or microscopic polyangiitis, followed at the French National Vasculitis Referral Center (09/2012-05/2013), and hospitalized non-AAV controls, exclusively for SA/SCV carriage comparisons, were enrolled. All had bilateral anterior nasal swab cultures. Nasal SA or SCV carriage was determined and associations with relapse(s), BVAS, ANCA-positivity, anti-staphylococcal and immunosuppressant use, were analysed ⩾4 years post-inclusion. RESULTS: Nasal SA carriage rates did not differ among AAVs (P = 0.53): GPA (24/80; 30%), EGPA (7/28; 25%) and microscopic polyangiitis (3/11; 27.3%); and the rate was less frequent in controls than in GPA patients not taking CTX (P = 0.04). AAV patients taking CTX prophylaxis had less nasal SA carriage (8.7% vs 36.2%; P = 0.02). Nasal SA carriage or CTX use did not modify relapse rates, BVAS or ANCA-positivity at inclusion or during follow-up. Nasal SCV carriage, found in 15/207 (7.2%) patients, was similar for GPA (10/24; 41.7%), microscopic polyangiitis (2/7; 28.6%) and eosinophilic GPA (2/3; 66.7%), but higher (P = 0.02) than controls (1/14; 7.1%). SCV carriage by AAV groups did not modify relapse rates or ANCA positivity at inclusion or during follow-up; a trend towards higher BVAS was observed only for anti-PR3 ANCA patients. CONCLUSION: Nasal SA or SCV carriage was comparable among AAVs but more frequent than in controls. Nasal SA or SCV carriage and CTX use did not modify AAV relapse rates.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Tan BK, Crabol Y, Tasse J, et al. No evident association of nasal carriage of Staphylococcus aureus or its small-colony variants with cotrimoxazole use or ANCA-associated vasculitis relapses. Rheumatology (Oxford). 2020. PMID: 31834404. doi:10.1093/rheumatology/kez236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。